Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP024: Childhood-onset inflammatory bowel disease and risk of cancer – a Swedish nationwide cohort study 1964–2014ECCO '17 Barcelona
Year: 2017
Authors:

Olén O.*1,2, Askling J.1, Frumento P.3, Sachs M.C.3, Neovius M.1, Eriksson J.1, Smedby K.E.1, Ekbom A.1, Malmborg P.1,2, Ludvigsson J.F.4,5,6,7

1Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Unit, Stockholm, Sweden 2Sachs' Children's Hospital, Department of Pediatric Gastroenterology and Nutrition, Stockholm, Sweden 3Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden 4Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden 5Orebro University Hospital, Department of pediatrics, Orebro, Sweden 6University of Nottingham, Division of Epidemiology and Public Health, School of Medicine, Nottingham, United Kingdom 7Columbia University College of Physicians and Surgeons, Department of Medicine, New York, Sweden

OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practiceECCO '17 Barcelona
Year: 2017
Authors:

Steiner S.*1, King E.2, Park K.3, Pashankar D.4, Shashidhar H.5, Sudel B.6, Eichner S.7, Chen S.2, Pratt J.2, Colletti R.8 ImproveCareNow Network, Burlington, United States

1Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, United States 2Cincinnati Children's Hospital Medical Center, Cincinnati, United States 3Lucile Salter Packard Children's Hospital, Stanford University, Palo Alto, United States 4Yale-New Haven Children's Hospital, New Haven, United States 5New Hampshire's Hospital for Children, Manchester, United States 6University of Minnesota Masonic Children's Hospital, Minneapolis, United States 7AbbVie, North Chicago, United States 8University of Vermont Childen's Hospital, Burlington, United States

OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Lahiff C.*1, Wang L.M.2, Travis S.P.L.1, East J.E.1

1Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Translational Gastroenterology Unit, Experimental Medicine Division, Oxford, United Kingdom 2John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Department of Cellular Pathology, Oxford, United Kingdom

OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in colitis-associated colorectal cancerECCO '17 Barcelona
Year: 2017
Authors:

Lopetuso L.R.*1,2, De Salvo C.3, Di Martino L.3, Goodman W.3, Scaldaferri F.4, Gasbarrini A.4, Pizarro T.T.3

1Catholic University of the Sacread Hearth, Internal Medicine, Gastroenterology Division, Rome, Italy 2Case Western Reserve University, Pathology, Cleveland, United States 3Case Western Reserve University, Pathology, Cleveland, United States 4Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy

OP028: Gut specific regulatory T cells – a new frontier for Crohn's disease therapyECCO '17 Barcelona
Year: 2017
Authors:

Goldberg R.*1,2,3,4, Scotta C.3,4,5, Cooper D.6, Eliraz E.7, Nir E.7, Irving P.1,8, Sanderson J.1,8, Shpigel N.7, Marelli-Berg F.6, Lombardi G.3,4,5, Lord G.2,3,4

1Guy's and St Thomas' NHS Trust, Gastroenterology, London, United Kingdom 2King's College London, Experimental Immunobiology, London, United Kingdom 3King's College London, Medical Research Council Centre for Transplantation, London, United Kingdom 4Guy's and St Thomas' NHS Trust, National Institute for Health Research Biomedical Research Centre, London, United Kingdom 5King's College London, Immunoregulation and Immune Intervention, London, United Kingdom 6Bart's and the London Queen Mary School of Medicine and Dentistry, William Harvey Research Institute, London, United Kingdom 7Hebrew University of Jerusalem, Koret School of Veterinary Medicine, Rehovot, Israel 8King's College London, Diabetes and Nutritional Sciences, London, United Kingdom

OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Lewis A.*1, Felice C.1,2, Nihjuis A.1, Iqbal S.1, Mehta S.1, Feakins R.3, Armuzzi A.2, Silver A.1, Lindsay J.4

1Queen Mary's University London, Centre for Genomics and Child Health, Blizard Institute, London, United Kingdom 2Gemelli Hospital Catholic University Foundation, IBD Unit, Presidio Columbus, Rome, Italy 3The Royal London Hospital, Department of pathology, London, United Kingdom 4Queen Mary's University London, Centre for Immunobiology, Blizard Institute, London, United Kingdom

OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantationECCO '17 Barcelona
Year: 2017
Authors:

Metwaly A.*1, Butt L.F.1, Waldschmitt N.1, Lagkouvardos I.2, Corraliza A.M.3, Mayorgas A.3, Martinez-Medina M.4, Allez M.5, Panes J.3, Salas A.3, Haller D.1,2

1Technical University Munich, Chair of Nutrition and Immunology, Freising, Germany 2ZIEL-Institute for Food and Health, Technical University of Munich, Freising, Germany 3Instituto de Investigaciones Biomédicas de Barcelona CSIC, IDIBAPS, CIBERehd, Department of Experimental Pathology, Barcelona, Spain 4Laboratory of Molecular Microbiology, Universitat de Girona, Biology Department, Girona, Spain 5APHP, Hôpital Saint Louis, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité University, Department of Gastroenterology, Paris, France

OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension studyECCO '17 Barcelona
Year: 2017
Authors:

Panés J.*1, D'Haens G.R.2, Higgins P.D.R.3, Mele L.4, Moscariello M.4, Chan G.4, Wang W.4, Niezychowski W.4, Su C.4, Maller E.4

1Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain 2Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands 3University of Michigan, Ann Arbor, MI, United States 4Pfizer Inc, Collegeville, PA, United States

OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trialECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Sands B.E.2, Danese S.3, D'Haens G.R.4, Vermeire S.5, Schreiber S.6, Feagan B.7, Reinisch W.8,9, Friedman G.10, Woodworth D.10, Zhang H.10, Lawendy N.10, Niezychowski W.10, Su C.10, Panés J.*11

1Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States 2Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States 3IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy 4Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands 5Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium 6Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany 7Robarts Clinical Trials, Inc., Robarts Research Institute, Western University, London, ON, Canada 8McMaster University, Hamilton, ON, Canada 9Medical University of Vienna, Vienna, Austria 10Pfizer Inc, Collegeville, PA, United States 11Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

OP033: Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitorECCO '17 Barcelona
Year: 2017
Authors:

Vermeire S.*1, De Hertogh G.2, Chen G.3, French D.4, Huntzicker E.4, Van der Aa A.5, Van Kaem T.5, Harrison P.5, Tasset C.5, Galien R.6, Pan Y.4, Feagan B.7, Sandborn W.8

1University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium 2University Hospitals Leuven, Department of Pathology, Leuven, Belgium 3Gilead Sciences, Department of Biostatistics, Foster City, United States 4Gilead Sciences, Biomarker Sciences, Foster City, United States 5Galapagos NV, Mechelen, Belgium 6Galapagos SASU, Romainville, France 7Robarts Resaerch Institute, Ontario, Canada 8University of California, Division of Gastroenterology, San Diego, United States

OP034: Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled studyECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Cyrille M.2, Hansen M.B.3, Feagan B.G.4, Loftus Jr. E.V.5, Rogler G.6, Vermeire S.7, Cruz M.L.2, Yang J.2, Sullivan B.A.2, Reinisch W.*8

1University of California San Diego, Department of Gastroenterology, La Jolla, United States 2Amgen, Thousand Oaks, United States 3University of Copenhagen, Copenhagen, Denmark 4Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada 5Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States 6Universitätsspital Zürich, Zürich, Switzerland 7University Hospital Gasthuisberg, Leuven, Netherlands 8Medical University of Vienna, Vienna, Austria

OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Cyrille M.2, Berner Hansen M.3, Feagan B.G.4, Loftus Jr. E.V.5, Vermeire S.6, Cruz M.L.2, Mo M.2, Sullivan B.A.2, Reinisch W.*7

1University of California San Diego, La Jolla, United States 2Amgen Inc., Thousand Oaks, United States 3University of Copenhagen, Copenhagen, Denmark 4Robarts Research Institute, University of Western Ontario, London, Canada 5Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States 6University Hospitals Leuven, Leuven, Belgium 7Medical University Vienna, Vienna, Austria

OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trialECCO '17 Barcelona
Year: 2017
Authors:

Costello S.*1,2,3, Waters O.4, Bryant R.2,3, Katsikeros R.3, Makanyanga J.4, Schoeman M.2,3, Mountifield R.5, Tee D.6, Howell S.2, Hughes P.2, Conlon M.7, Roberts-Thomson I.1,2, Andrews J.2,3

1The Queen Elizabeth Hospital, Gastroenterology, Woodville, Australia 2University of Adelaide, School of Medicine, Adelaide, Australia 3The Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia 4Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia 5Flinders Medical Centre, Gastroenterology, Bedford Park, Australia 6Lyell McEwin Hospital, Gastroenterology, Elizabeth Vale, Australia 7CSIRO, Health and Biosecurity, Adelaide, Australia

OP037: Infants born to mothers with inflammatory bowel disease exhibit distinct microbiome features that persist up to 3 months of lifeECCO '17 Barcelona
Year: 2017
Authors:

Torres J.*1, Hu J.2, Eisele C.2, Nair N.2, Panchal H.2, Bao X.2, Niu X.2, Côté-Daigneault J.1, Jharap B.1, Maser E.1, Kornbluth A.1, Legnani P.1, George J.1, Dubinsky M.3, Stone J.4, Chen C.-L.4, Clemente J.2,5, Colombel J.-F.1, Peter I.2

1Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States 2Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences, New York, United States 3Icahn School of Medicine at Mount Sinai, Department of Pediatrics, New York, United States 4Icahn School of Medicine at Mount Sinai, Obstetrics, Gynecology and Reproductive Science, New York, United States 5Icahn School of Medicine at Mount Sinai, Immunology, New York, United States

OP038: Impact of ileocecal resection in Crohn's disease patients on mucosal microbiotaECCO '17 Barcelona
Year: 2017
Authors:

Machiels K.*1, Pozuelo del Río M.2, Sabino J.1, Santiago A.2, Campos D.2, Wolthuis A.3, De Buck van Overstraeten A.3, D'Hoore A.3, Van Assche G.1, Ferrante M.1, Rutgeerts P.1, De Hertogh G.3, Vermeire S.1, Manichanh C.2

1University Hospitals Leuven, KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium 2Vall d'Hebron Research Institute, Barcelona, Spain 3University Hospitals Leuven, KU Leuven, Leuven, Belgium

P001: The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, tracks with efficacy in a preclinical model of IBDECCO '17 Barcelona
Year: 2017
Authors:

Cheng X., Taranath R., Mattheakis L., Bhandari A., Liu D.

Protagonist Therapeutics, Milpitase, United States

P002: Inhibition of Axl signaling by BGB324 reduces fibrogenesis in human intestinal cells and human intestinal organoidsECCO '17 Barcelona
Year: 2017
Authors:

Steiner C.1, Rodansky E.2, Johnson L.A.2, Huang S.2, Spence J.1, Higgins P.D.*3

1University of Michigan, Internal Medicine - Gastroenterology, Ann Arbor, United States 2University of Michigan, Internal Medicine - Gastroenterology, Ann Arbor, Michigan, United States 3University of Michigan, Internal Medicine - Gastroenterology, Ann Arbor, MI, United States

P004: Stimulation of CYP450-mediated ω-3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Ungaro F.*1,2, Tacconi C.3, Correale C.4, Massimino L.5, Corsetto P.6, Piontini A.2,4, Fonteyne P.7, Calcaterra F.8, Della Bella S.8, Spinelli A.8, Carvello M.8, Rizzo A.6, Vetrano S.2,4, Fiorino G.4,8, Furfaro F.4,8, Maddipati K.R.9, D'Alessio S.4,10, Danese S.2,4

1Humanitas Research Institute, Laboratory of Immunology in Gastroenterology, Rozzano, Italy 2Humanitas University, Rozzano, Italy 3Swiss Federal Institute of Technology, Zurich, Switzerland 4Humanitas Research Institute, Laboratory of Immunology in Gastroenterology, Milan, Italy 5University of Milan, School of Medicine and Surgery, Milan, Italy 6University of Milan, Department of Pharmacology and Biomolecular Science, Milan, Italy 7San Raffaele Research Institute, Milano, Italy 8Humanitas Research Institute, Rozzano, Italy 9Wayne State University, Department of Pathology, Detroit, United States 10University of Milan, Department of Biotechnology and Translational Medicine, Milan, Italy

P005: Establishing a porcine model to translate anorectal stem cell organoid models to elucidate the aetiology of perianal Crohn's fistulaeECCO '17 Barcelona
Year: 2017
Authors:

Adegbola S.*1, Moore J.2, Sahnan K.1, Tozer P.1, Phillips R.1, Warusavitarne J.3, Faiz O.1, Hart A.4

1St Mark's Academic Institute, Surgery, London, United Kingdom 2Curileum Discovery Ltd, Northwick Park Institute of Medical Research/St Mark's Hospital Site, London, United Kingdom 3St Mark's Hospital, London, London, United Kingdom 4St Mark's Academic Institute, Gastroenterology, London, United Kingdom

P006: Transcriptomic profiling of intestinal macrophages isolated from patients reveals a profound gene expression reprogramming underlying IBD pathogenesisECCO '17 Barcelona
Year: 2017
Authors:

Dharmasiri S.*1,2, Garrido Martin E.M.2, Sanchez-Elsner T.2, Cummings J.R.F.1

1Southampton General Hospital, Department of Gastroenterology, Southampton, United Kingdom 2University of Southampton, Department of Clinical and Experimental Sciences, Southampton, United Kingdom